Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

American Society of Clinical Oncology (ASCO) - Tập 32 Số 12 - Trang 1210-1217 - 2014
Robert A. Burger1, Mark F. Brady1, Michael A. Bookman1, Bradley J. Monk1, Joan L. Walker1, Howard D. Homesley1, Jeffrey M. Fowler1, Benjamin E. Greer1, Matthew Boente2,1, Gini F. Fleming1, Peter Lim1, Stephen C. Rubin1, Noriyuki Katsumata1, Sharon X. Liang1
1Robert A. Burger, Fox Chase Cancer Center, Philadelphia, PA; Mark F. Brady, GOG Statistical and Data Center, Buffalo, NY; Michael A. Bookman, Arizona Cancer Center, Tucson, AZ; Bradley J. Monk, University of California at Irvine, Orange, CA; Joan L. Walker, University of Oklahoma, Oklahoma City, OK; Howard D. Homesley, Wake Forest University Medical Center, Winston-Salem, NC; Jeffrey Fowler, Ohio State University, Columbus, OH; Benjamin E. Greer, University of Washington Medical Center, Seattle, WA;...
2 Matthew Boente, Minnesota Oncology Hematology, Minneapolis, MN

Tóm tắt

Purpose To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in first-line ovarian cancer therapy. Patients and Methods Women with previously untreated advanced disease after surgery were randomly allocated to six cycles of platinum-taxane chemotherapy plus placebo cycles (C)2 to C22 (R1); chemotherapy plus bevacizumab C2 to C6 plus placebo C7 to C22 (R2); or chemotherapy plus bevacizumab C2 to C22 (R3). Patients were evaluated for history or on-study development of potential risk factors for GI AEs defined as grade ≥ 2 perforation, fistula, necrosis, or hemorrhage. Results Of 1,873 patients enrolled, 1,759 (94%) were evaluable, and 2.8% (50 of 1,759) experienced a GI AE: 10 of 587 (1.7%, R1), 20 of 587 (3.4%, R2), and 20 of 585 (3.4%, R3). Univariable analyses indicated that previous treatment of inflammatory bowel disease (IBD; P = .005) and small bowel resection (SBR; P = .032) or large bowel resection (LBR; P = .012) at primary surgery were significantly associated with a GI AE. The multivariable estimated relative odds of a GI AE were 13.4 (95% CI, 3.44 to 52.3; P < .001) for IBD; 2.05 (95% CI, 1.09 to 3.88; P = .026) for LBR; 1.95 (95% CI, 0.894 to 4.25; P = .093) for SBR; and 2.15 for bevacizumab exposure (aggregated 95% CI, 1.05 to 4.40; P = .036). Conclusion History of treatment for IBD, and bowel resection at primary surgery, increase the odds of GI AEs in patients receiving first-line platinum-taxane chemotherapy for advanced ovarian cancer. After accounting for these risk factors, concurrent bevacizumab doubles the odds of a GI AE, but is not appreciably increased by continuation beyond chemotherapy.

Từ khóa


Tài liệu tham khảo

Byrne AT, 2003, Clin Cancer Res, 9, 5721

10.1016/j.ygyno.2004.05.056

10.1158/1535-7163.MCT-04-0305

10.1158/1541-7786.MCR-07-0366

10.1038/sj.bjc.6604921

10.1158/1078-0432.CCR-04-0056

Hollingsworth HC, 1995, Am J Pathol, 147, 33

10.1111/j.1048-891X.2004.014514.x

10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A

10.1002/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6

Siddiqui GK, 2010, Eur J Gynaecol Oncol, 31, 156

10.1111/IGC.0b013e3181a13168

Alvarez AA, 1999, Clin Cancer Res, 5, 587

10.1054/bjoc.2000.1228

10.1158/1078-0432.CCR-07-1888

10.1016/S0002-9440(10)65669-6

Xu L, 2000, Int J Oncol, 16, 445

Presta LG, 1997, Cancer Res, 57, 4593

10.1200/JCO.2007.11.5345

10.1200/JCO.2007.12.0782

10.1200/JCO.2012.42.0505

10.1056/NEJMoa1104390

10.1056/NEJMoa1103799

10.1200/jco.2012.30.18_suppl.lba5002

Full Prescribing Information 2013 Avastin http://www.gene.com/download/pdf/avastin_prescribing.pdf

Cox DR, 1970, The Analysis of Binary Data

10.1002/0471722146

Cox DR, 1984, Analysis of Survival Data

10.1016/S1470-2045(09)70112-3

10.1016/j.ygyno.2009.11.017

10.1007/s10637-008-9125-4

10.1006/jsre.1998.5551

10.1093/emboj/19.13.3272

10.1159/000018820

10.1245/aso.2002.9.3.303

10.1096/fj.00-0490fje

10.1002/bjs.1800831038

10.1046/j.0022-202x.2001.01519.x

10.1006/jsre.2000.5890

10.1245/s10434-006-9337-9

10.1200/jco.2006.24.18_suppl.3535

10.1007/s10637-010-9505-4

10.1016/j.ygyno.2007.01.038

10.1007/s10637-008-9162-z

10.1007/s10456-004-8272-2

10.1016/j.cursur.2006.06.002

10.1007/s11605-010-1190-2

10.1046/j.0007-1323.2001.01829.x

10.1111/j.1463-1318.2006.01002.x

10.1016/j.ygyno.2006.05.003

10.1056/NEJMoa0908806

10.1016/j.ygyno.2007.09.008

10.1006/gyno.1997.4842

10.1016/j.ygyno.2009.05.031

10.1006/gyno.1995.1140

Katz S, 1986, Am J Gastroenterol, 81, 38

Greenstein AJ, 1985, Am J Gastroenterol, 80, 682

10.1097/00000658-198701000-00013

10.1016/j.mcna.2008.01.003

10.1016/j.lungcan.2003.11.018

10.1016/S0140-6736(09)61157-0

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 32 Số 12

1210-1217

Thông tin tác giả